|
|
||||||||||||||
|
|
|||||||||||||||
The Hatter
Institute, Department of Academic & Clinical Cardiology, University
College London Hospitals & Medical School, Grafton Way, London
WC1E 6DB, UK
Correspondence to: Professor Yellon email: hatter-institute@ucl.ac.uk
Accepted 6 January 2000
| The first 150 words of the full text of this article appear below. |
| |
Introduction |
|---|
Acute
coronary occlusion is the leading cause of morbidity and mortality in
the Western world, and according to the World Health Organisation will
be the major cause of death in the world as a whole by the year
2020.1 Although the management of this epidemic will
centre on the development of effective primary prevention programmes,
the impact of these strategies may be limited, particularly in the
developing countries. There is an urgent need for effective forms of
secondary prevention and, in particular, treatments which will limit
the extent of an evolving myocardial infarction during the acute phase
of coronary occlusion
the death of myocardium represents a
catastrophic event since dead myocytes are not replaced by division of
surviving myocytes. Preserving the viability of ischaemic myocardium
therefore presents a therapeutic target. Although appreciated for many
years, this concept has so far failed to produce a clinically useful
agent capable of protecting
This article has been cited by other articles:
![]() |
A T Ratcliffe and C Pepper Thrombolysis or primary angioplasty? Reperfusion therapy for myocardial infarction in the UK Postgrad. Med. J., February 1, 2008; 84(988): 73 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sexton, M. McDonald, C. Cayla, C. Thiemermann, and A. Ahluwalia 12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1 FASEB J, September 1, 2007; 21(11): 2695 - 2703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Zarich and R. W. Nesto Implications and Treatment of Acute Hyperglycemia in the Setting of Acute Myocardial Infarction Circulation, May 8, 2007; 115(18): e436 - e439. [Full Text] [PDF] |
||||
![]() |
F. Ikeno, K. Inagaki, M. Rezaee, and D. Mochly-Rosen Impaired perfusion after myocardial infarction is due to reperfusion-induced {delta}PKC-mediated myocardial damage Cardiovasc Res, March 1, 2007; 73(4): 699 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Bar, D. Tzivoni, M. T. Dirksen, A. Fernandez-Ortiz, G. R. Heyndrickx, J. Brachmann, J. H.C. Reiber, N. Avasthy, J. Tatsuno, M. Davies, et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study Eur. Heart J., November 1, 2006; 27(21): 2516 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Burdess and D Newby Harnessing the preconditioning phenomenon: does remote organ ischaemia provide the answer? Heart, October 1, 2006; 92(10): 1367 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Darling, R. Jiang, M. Maynard, P. Whittaker, J. Vinten-Johansen, and K. Przyklenk Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2 Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1618 - H1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Murriel, E. Churchill, K. Inagaki, L. I. Szweda, and D. Mochly-Rosen Protein Kinase C{delta} Activation Induces Apoptosis in Response to Cardiac Ischemia and Reperfusion Damage: A MECHANISM INVOLVING BAD AND THE MITOCHONDRIA J. Biol. Chem., November 12, 2004; 279(46): 47985 - 47991. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Jiang, W. Srisakuldee, F. Soulet, G. Bouche, and E. Kardami Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion Cardiovasc Res, April 1, 2004; 62(1): 154 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Dai and R. A. Kloner Effects of Acetaminophen on Myocardial Infarct Size in Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 277 - 284. [Abstract] [PDF] |
||||
![]() |
K. Inagaki, L. Chen, F. Ikeno, F. H. Lee, K.-i. Imahashi, D. M. Bouley, M. Rezaee, P. G. Yock, E. Murphy, and D. Mochly-Rosen Inhibition of {delta}-Protein Kinase C Protects Against Reperfusion Injury of the Ischemic Heart In Vivo Circulation, November 11, 2003; 108(19): 2304 - 2307. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rosa, J.-P. Maury, J. Terrand, X. Lyon, P. Kucera, L. Kappenberger, and E. Raddatz Ectopic pacing at physiological rate improves postanoxic recovery of the developing heart Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2384 - H2392. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Sack and D. M. Yellon Insulin therapy as an adjunct toreperfusion after acute coronary ischemia: A proposed direct myocardial cell survival effect independent of metabolic modulation J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1404 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Bell and D. M. Yellon Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway J. Am. Coll. Cardiol., February 5, 2003; 41(3): 508 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Maddock, M. M. Mocanu, and D. M. Yellon Adenosine A3 receptor activation protects the myocardium from reperfusion/reoxygenation injury Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1307 - H1313. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Q. Zhao and J. Vinten-Johansen Myocardial apoptosis and ischemic preconditioning Cardiovasc Res, August 15, 2002; 55(3): 438 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verma, P. W.M. Fedak, R. D. Weisel, J. Butany, V. Rao, A. Maitland, R.-K. Li, B. Dhillon, and T. M. Yau Fundamentals of Reperfusion Injury for the Clinical Cardiologist Circulation, May 21, 2002; 105(20): 2332 - 2336. [Full Text] [PDF] |
||||
![]() |
I. B. A. Menown and A. A. J. Adgey Cardioprotective therapy and sodium-hydrogen exchange inhibition: current concepts and future goals J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1651 - 1653. [Full Text] [PDF] |
||||
![]() |
C.H. Davies Revascularization for cardiogenic shock QJM, February 1, 2001; 94(2): 57 - 67. [Full Text] [PDF] |
||||
![]() |
Z.-S. Jiang, R. R. Padua, H. Ju, B. W. Doble, Y. Jin, J. Hao, P. A. Cattini, I. M. C. Dixon, and E. Kardami Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1071 - H1080. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |